Cardionogen 1
Based on 1 publication(s) in Google Scholar
Cardionogen 1 (CDNG1/vuc230) is a Wnt signaling pathway inhibitor that slows down Myc-induced liver tumorigenesis. Cardionogen 1 treatment of zebrafish embryos before gastrulation inhibits cardiomyocyte formation, whereas treatment during or after gastrulation induces cardiomyocyte formation. Cardionogen 1 has potential in research into cancer and cardiovascular disease.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.21%
- CAS 番号: 577696-37-8
- 分子式: C13H14N4OS
- 分子量:274.34
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-12238
IWR-1Wnt Signaling Inhibitor -
HY-13912
IWP-2Wnt Production Inhibitor -
HY-12681
CCT251545WNT Pathway Inhibitor -
HY-15659
Wnt-C59PORCN Inhibitor -
HY-108442
JW67Wnt Signaling Inhibitor -
HY-16665
iCRT 14Wnt Inhibitor -
HY-115539
WindorphenWnt/β-catenin Inhibitor -
HY-15721
FH535Wnt/β-catenin/PPAR Inhibitor -
HY-12879
IWP-4Wnt/CK1δ/ε Inhibitor -
HY-19987
BML-284Wnt Signaling Activator -
HY-101130
PNU-74654β-catenin/TCF Interaction Inhibitor -
HY-122816
HLY78Wnt/β-catenin Activator
MedChemExpress（MCE）の使用を引用している文献 Cardionogen 1
More
生物活性
製品説明
化学情報
-
CAS 番号 577696-37-8
-
性状 Solid
-
分子量 274.34
-
分子式 C13H14N4OS
-
Color White to off-white
-
SMILES
C12=NN=C(C3=CC=CO3)N1N=C(C4CCCCC4)S2
-
別名
CDNG1/vuc230
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
プロトコル
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
純度とドキュメンテーション
-
データシート (270 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Yan C, et al. Chemical inhibition reveals differential requirements of signaling pathways in krasV12- and Myc-induced liver tumors in transgenic zebrafish. Sci Rep. 2017 Apr 5;7:45796. [Content Brief]
[2]. Plowright AT, et al. Heart regeneration: opportunities and challenges for drug discovery with novel chemical and therapeutic methods or agents. Angew Chem Int Ed Engl. 2014 Apr 14;53(16):4056-75. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Cardionogen 1 関連分類
HY-W011616 関連分類
Powered by Bioz